An example of a SAVE-P CPAP ventilator, pictured here within a specially sealed manufacturing cubicle. (Supplied, SAVE-P) A Durban-based non-profit has received regulatory approval for a locally produced non-invasive ventilator for Covid-19 patients.The approval comes after months of work and preparation.The design is based on a 40-year-old machine made by UK-based company, Penlon.A group of…
The National Lotteries Commission paid R22.5 million to an organisation called WAR_RnA to build an old age home.The organisation was dormant and the directors had no knowledge of the grant.The old age home was supposed to be completed in March 2020, but as of end of May was still incomplete.The police told a registered director…
Solidarity Helping Hand says it is preparing to take legal action against the government for allegedly centralising food distribution to the poor.In a statement on Monday, the organisation said it would take legal action "should [the government] continue to implement regulations prescribing that the distribution of food to the poor be centralised under government control"."It…
You don't have permission to access "http://www.cpsc.gov/Recalls/2026/Feel-The-Beard-Recalls-Minoxidil-Beard-Growth-Serum-Bottles-Due-to-Risk-of-Serious-Injury-or-Death-from-Child-Poisoning-Violates-Mandatory-Standard-for-Child-Resistant-Packaging" on this server. Reference #18.525ed617.1766127707.117863be https://errors.edgesuite.net/18.525ed617.1766127707.117863be
This ruby red sweater is made for Christmas—richly festive without going over the top. The Italian alpaca-wool blend is naturally warm and slightly fuzzy, giving it a soft, textured finish that feels richer than standard merino. Alpaca adds lightweight insulation, so it keeps you warm without bulk, while wool helps regulate temperature, whether you’re inside
Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire disorder (HSDD)—had no dedicated treatment option available to them. But that changed on December 15, 2025, when the FDA expanded its approval for the prescription drug Addyi (flibanserin), which was approved in 2015 to treat HSDD in premenopausal